Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
funding
Biotech
Storm secures $56M series C, launches ph. 2 sarcoma trial
Former Fierce 15 honoree Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial for sarcoma patients.
Will Maddox
Apr 16, 2026 10:12am
Stipple Bio debuts with $100M to advance oncology asset
Apr 6, 2026 7:00am
Ambrosia scores $100M series B to advance next-gen oral GLP-1
Mar 31, 2026 10:02am
Biopharma funding fell 20% in 2025: IQVIA
Mar 26, 2026 6:01am
Mainz Biomed looks to shed ColoAlert
Feb 20, 2026 7:50am
Santé Ventures closes $330M fund for biotech, medtech and more
Feb 2, 2026 8:15am
